Clinical Trials Browser

Phase 2 × Interventional × Acrocephalosyndactylia × Clear all

NCT04238715 2026-03-02

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Phase 2 Completed

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT03822117 2025-11-04

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Phase 2 Terminated

111 enrolled 17 charts

Acrocephalosyndactylia

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04962867 2025-10-03

NCCH2006/MK010 Trial (FORTUNE Trial)

Phase 2 Recruiting

Acrocephalosyndactylia

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Phase 2 Completed

263 enrolled 20 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Phase 2 Completed

147 enrolled 22 charts 1 FDA

Gastrointestinal

Acrocephalosyndactylia, Cholangiocarcinoma

NCT05253807 2025-08-05

FIGHT-210

Phase 2 Completed

8 enrolled 13 charts

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02699606 2025-04-27

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Phase 2 Completed

GastrointestinalThoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Cholangiocarcinoma

NCT03762122 2022-11-09

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Phase 2 Terminated

Acrocephalosyndactylia

NCT05019794 2022-06-27

FGFR

Phase 2 Unknown

Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Phase 2 Completed

BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT01367275 2020-09-03

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Phase 2 Terminated

8 enrolled 5 charts

Gastrointestinal

Acrocephalosyndactylia, Colorectal Neoplasms

NCT02747797 2018-08-02

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms

NCT02846766 2018-08-02

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms